Lexicon Pharmaceuticals Inc (LXRX) stock saw a decline, ending the day at $0.96 which represents a decrease of $-0.03 or -3.03% from the prior close of $0.99. The stock opened at $0.99 and touched a ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $212.73, a high ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 1.49% of ...

Beta Bionics (BBNX), a developer of insulin delivery devices, has set terms for an upsized $165M initial public offering.

Beta Bionics is targeting a valuation of up to $695 million in an upsized initial public offering, the insulin delivery device maker said on Tuesday. The company will aim to raise up to $170 million ...

Leerink Partners made an adjustment to Regeneron Pharmaceuticals' (NASDAQ:REGN) stock, reducing the price target from $880 to $762 while maintaining a Market Perform rating. The stock, currently ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on BMY stock, giving a Buy rating on January 12.Invest with ...

Analyst David Risinger from Leerink Partners reiterated a Buy rating on Tectonic Therapeutic (TECX – Research Report) and increased the price ...

CICC Research initiated coverage on shares of Intuitive Surgical (NASDAQ:ISRG – Free Report) in a research note issued to ...